Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M

Cytek Biosciences, Inc.

2021-FY EPS reported $0.00 revenue$127,950,000

Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).
Q4 net income $0.3M (vs $5.6M in Q4 2020); FY net income $4.4M (vs $19.4M in 2020).
Adjusted EBITDA Q4 $5.5M; FY $17.5M, up from $15.4M in 2020.
Installed base 1,110 instruments; 453 instrument placements in FY2021.
FY2022 revenue guidance $160-168M, representing 25-31% growth over FY2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.